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Open Forum Infectious Diseases
Impact of Obesity on Acyclovir-Induced Nephrotoxicity
Katie E. Barber, Jamie L. Wagner,  and Kayla R. Stover
Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi
Background. Obesity is a major medical issue nationally, with rates continually increasing. In obese patients, minimal data exist 
for appropriate dosing of acyclovir to decrease the rates of nephrotoxicity. The purpose of this study was to determine the prevalence 
of and risk factors associated with acyclovir-induced nephrotoxicity.
Methods. A retrospective case–control of patients who received intravenous acyclovir for >48 hours at the University of 
Mississippi Medical Center over a 4-year period were evaluated to elucidate the prevalence of acyclovir-induced nephrotoxicity. 
Additionally, risk factors for the development of nephrotoxicity, including the effect of obesity and dosing strategy, were assessed.
Results. One hundred fifteen patients were included in the study. A total of 24 (21%) patients developed nephrotoxicity after 
acyclovir exposure and were in the Risk (9.6%), Injury (4.3%), and Failure (7%) categories, defined by the RIFLE criteria. Neither 
acyclovir dosage, fluid status, nor baseline characteristics, other than obesity, varied between those who developed nephrotoxicity 
vs those who did not. Independent predictors of nephrotoxicity were obesity (odds ratio [OR], 3.2; 95% confidence interval [CI], 
1.19–8.67) and receipt of vancomycin (OR, 4.73; 95% CI, 1.57–14.25). No differences in vancomycin dosing or concentrations were 
observed between the patients who developed nephrotoxicity and those who did not.
Conclusions. In this study, nephrotoxicity occurred in 21% of patients receiving acyclovir. Concomitant vancomycin receipt and 
obesity led to higher rates of toxicity. Efforts should be made to target obese patients on acyclovir plus vancomycin and discontinue 
therapy in patients not warranting antiviral coverage to minimize chances of toxicity.
Keywords.  acyclovir; antimicrobial stewardship; HSV; nephrotoxicity.
Obesity is a major medical issue nationally, leading to health 
complications, morbidity, and mortality. National rates indicate 
that >35% of adults are obese, with states where large portions 
of the population have low access to care, including Louisiana, 
Mississippi, Alabama, and West Virginia, each reporting even 
higher rates [1, 2]. In patients who are obese, clinicians are often 
challenged regarding how to properly address medical issues, 
especially with medications that require dosing based upon 
body weight.
Although some weight-based antimicrobials have 
recommendations for use of either actual body weight (ABW) 
or ideal body weight (IBW), many of these drugs have little ev-
idence available to guide clinician dosing. With the increasing 
rates of obesity and morbid obesity, ABW and IBW are increas-
ingly divergent, prompting many clinicians to perform dosage 
calculations based upon an adjusted body weight (AdjBW), a 
calculated value that falls between the IBW and ABW.
Acyclovir, approved in 1982 for the treatment of herpes sim-
plex virus (HSV), is one such drug that is dosed according to 
weight [3]. A  single study evaluated the pharmacokinetics of 
acyclovir in 7 morbidly obese patients and 5 normal-weight 
patients and displayed similar pharmacokinetics between 
groups [4]. Because obese patients displayed comparable phar-
macokinetics as normal-weight persons and given data that 
demonstrate increased dosages resulting in higher rates of 
nephrotoxicity from 12% to 48% [5–7], the recommendation 
for IBW dosing was chosen.
Unfortunately, no data exist regarding the rates of nephrotox-
icity between the potential dosing weights or the specific cause 
of nephrotoxicity in the adult population (ie, direct toxicity from 
acyclovir vs a combination of risk factors). Identification of these 
risk factors will aid clinicians in providing an evidence-based 
approach to current clinical practice, thus providing a higher 
quality of care to all patients receiving acyclovir. The purpose 
of this study was to determine the prevalence of and risk factors 
for acyclovir-associated nephrotoxicity in an adult population 
at the University of Mississippi Medical Center (UMMC).
METHODS
Study Design, Setting, and Patient Population
A retrospective case–control study was conducted at UMMC 
among adult (≥18  years old) patients who received intrave-
nous (IV) acyclovir for >48 hours between January 1, 2014, and 
December 31, 2014. UMMC is a university-affiliated tertiary 
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hospital and referral center with >700 inpatient beds. Patients 
were identified through use of clinical decision support soft-
ware (TheraDoc). Excluded patients were those receiving he-
modialysis or other forms of renal replacement therapy before 
the receipt of acyclovir and those on vasoactive medications. If a 
patient received more than 1 course of IV acyclovir, subsequent 
exposures were not included. Included patients were analyzed 
to determine the frequency of IV acyclovir–associated nephro-
toxicity. The patients were divided into 2 groups: those who de-
veloped toxicity (cases) and those who did not (controls).
Study Variables and Definitions
Demographics (patient age, gender, race, weight, and 
comorbidities), microbiological data, intensive care unit (ICU) 
status, and presence of infectious diseases consultation were col-
lected. Additional data collected included information pertaining 
to the primary study end point of nephrotoxicity: weight-based 
dose, baseline renal function (obtained the day before acy-
clovir initiation), renal function while on IV acyclovir therapy, 
new-onset renal replacement therapy, and reduction in or dis-
continuation of acyclovir. Lastly, known risk factors for nephro-
toxicity were also collected, including concomitant nephrotoxic 
agents (aminoglycosides, vancomycin, angiotensin-converting 
enzyme inhibitors, and radiocontrast dye) and hydration status 
(concomitant fluids). Obesity was defined per the World Health 
Organization as a body mass index (BMI) ≥30. Nephrotoxicity 
was defined according to the RIFLE criteria, which were calcu-
lated with the highest serum creatinine value during acyclovir 
therapy [8]. In the microbiologically evaluable population (those 
with punch biopsy–proven or polymerase chain reaction [PCR]–
proven viral infection), therapeutic success was assessed via re-
turn to baseline mentation for central nervous system (CNS) 
involvement or reduction in size, frequency, or crusting of lesions 
for cutaneous infections. Acyclovir dosing was recorded as milli-
gram per kilogram of ABW, AdjBW, and IBW.
Statistical Analyses
Statistical analysis was performed using SPSS software, version 
23.0 (IBM). Categorical data were analyzed using the chi-square 
or Fisher exact test, and continuous data were analyzed using the 
Student t test or Mann-Whitney U test, as appropriate. An alpha 
of ≤.05 was deemed statistically significant. Variables that had a 
P value <.2 on univariate analysis or that were deemed clinically 
relevant by the investigators were evaluated for inclusion in a 
multivariable logistic regression model, and adjusted odds ratios 
(ORs) with associated confidence intervals (CIs) were calculated. 
Clinically relevant was defined as variables with prior documen-
tation of contributing to the development of nephrotoxicity.
RESULTS
A total of 115 patients were enrolled in the study. Patient char-
acteristics are listed in Table 1. The median age (interquartile 
range [IQR]) was 54 (37–64) years, with a predominately female 
(52%) population. Among the 115 patients, acyclovir-associated 
nephrotoxicity, defined by the RIFLE criteria, was observed in 
24 (21%) patients. Among those who developed nephrotoxicity, 
there were 11 (9.6%) in the Risk category (serum creatinine 
increased 1.5× over baseline), 5 (4.3%) in the Injury category 
(serum creatinine increased 2× over baseline), and 8 (7%) in the 
Failure category (serum creatinine increased 3× over baseline). 
No patients experienced loss of renal function beyond 4 weeks.
In univariate analysis, obesity was the only comorbid con-
dition associated with nephrotoxicity (P  =  .04). There were 
no differences in receipt or type of IV hydration or concom-
itant nephrotoxic agents, other than receipt of vancomycin. 
Although 63 (55%) patients received vancomycin, there were 
no differences between the 2 groups on maximum vancomycin 
dose (P = .76), frequency of initial trough >20 mg/L (P = .71), or 
maximum total daily dosage (P = .52). Furthermore, there were 
no differences between groups in trough concentrations for any 
troughs obtained throughout vancomycin therapy. Baseline 
serum creatinine values were similar between groups, with a 
median initial value of 0.75 mg/dL (P = .09). As expected, the 
patients who developed nephrotoxicity displayed higher serum 
creatinine values, with the peak values observed at a median 
(IQR) of day 4.5 (3–7) of acyclovir therapy. Of the patients who 
developed nephrotoxicity, 4 (17%) needed renal replacement 
therapy. More patients (50% vs 22%) who experienced nephro-
toxicity were admitted to the ICU during their hospitalization 
compared with control patients (P  =  .01). These patients also 
had longer stays in the ICU, at a median (IQR) of 10.5 (7–14.8) 
days vs 5 (3–7.5) days, respectively (P  =  .01). Although total 
length of stay was comparable between both groups, the length 
of stay postinitiation of acyclovir therapy was 4 days longer in 
the patients who developed nephrotoxicity (P = .03).
All patients were initiated on thrice-daily dosing of acyclovir. 
The median total daily dose (IQR) was 1950 (1575–2325) mg, 
with a median dose of 10.1 (9.9–11.4) mg/kg and 8.1 (6.0–10.2) 
mg/kg based upon IBW and ABW, respectively. There were no 
differences observed between either group (P = .67). Acyclovir-
associated nephrotoxicity was not associated with dosing weight 
utilized (P > .05). Patients who developed nephrotoxicity were 
treated with acyclovir for a median (IQR) of 8.5 (5.25–11) days, 
whereas the control group was treated with acyclovir for a me-
dian of 6 (5–9) days (P = .053).
The majority (62%) of patients initiated on acyclovir therapy 
had an indication for treatment of a CNS infection. However, 
only 17 (15%) patients had positive microbiological results, 
with the most commonly identified organism being HSV. There 
were no differences between groups in indication for acyclovir, 
infection site, time to baseline mentation, or time to lesion size 
reduction and lesion crusting.
The majority (80.9%) of patients were on additional agents 
known to cause nephrotoxicity, with the most frequently 
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identified concomitant nephrotoxin being vancomycin. 
Although more patients in the nephrotoxicity group received 
vancomycin, there were no differences in maximum cumula-
tive daily dosage, maximum total dosage, frequency of dosing, 
or initial trough values. In multivariate logistic regression, both 
obesity (OR, 2.67; 95% CI, 1.04–6.86) and receipt of vanco-
mycin (OR, 4.06; 95% CI, 1.40–11.80) were independently as-
sociated with increased nephrotoxicity (Table 2).
CONCLUSIONS
Approximately one-fifth of the patients included developed 
acyclovir-associated nephrotoxicity after approximately 5 days 
of therapy. Although obesity was the only comorbidity differ-
ence between the cases and controls, the total daily acyclovir 
dosage did not differ between the 2 groups. Although many 
patients received concomitant nephrotoxins, there was an 
equivalent distribution other than the receipt of vancomycin. 
However, patients in both groups had comparable vancomycin 
dosing and trough concentrations. Both vancomycin receipt 
and obesity were independent risk factors for the development 
for acyclovir-associated nephrotoxicity, leading to numerically 
increased length of hospital stay and statistically increased 
length of stay after acyclovir initiation.
Published rates of acyclovir-associated nephrotoxicity range 
between 12% and 48% [5, 9, 10]. However, the effect of obesity 
has not been definitively defined, though several case reports 
have suggested that weight may be the culprit [11, 12]. Our 
study demonstrated comparable findings with a 21% rate of 
nephrotoxicity. Additionally, obesity was an independent pre-
dictor of nephrotoxicity in these patients. Unfortunately, there 
currently is not a consensus on how acyclovir should be dosed 
in these patients. An abstract presented at the Interscience 
Conference on Antimicrobial Agents and Chemotherapy in 
1991 suggested that morbidly obese patients should be dosed ac-
cording to IBW based upon excessive acyclovir concentrations 
in 7 morbidly obese vs 5 normal-weight patients utilizing ABW 
[4]. Conversely, Turner and colleagues evaluated IBW dosing 
of acyclovir in 14 patients, 7 of whom were morbidly obese, 
and determined that systemic exposure in the morbidly obese 
patients provided substantially lower exposure than that of the 
nonobese patients [13]. Although obesity was a risk factor for 
Table 1. Patient Demographics
 Total Population (n = 115) Toxicity Group (n = 24) Nontoxicity Group (n = 91) P Value
Age, y 54 [37–64] 55 [45–66] 52 [35–64] .39
Male 55 (47.8) 9 (37.5) 45 (50.5) .26
Comorbid conditions
Obese 55 (47.8) 16 (66.7) 38 (42.9) .04
Diabetes 35 (30.4) 6 (25) 29 (31.9) .52
Dyslipidemia 15 (13) 5 (20.8) 10 (11) .30
Hypertension 62 (53.9) 16 (66.7) 46 (50.5) .35
Heart failure 8 (7) 3 (12.5) 5 (5.5) .36
Chronic kidney disease 12 (10.4) 3 (12.5) 9 (9.9) .71
Cancer 64 (55.7) 11 (45.58) 53 (58.2) .28
Renal transplant 1 (0.9) 0 (0) 1 (1.1) 1.00
Concomitant nephrotoxic agents
ACE inhibitors 17 (14.8) 6 (25) 11 (12.1) .19
Aminoglycosides 1 (0.9) 0 (0) 1 (1.1) 1.00
Amphotericin 4 (3.5) 1 (4.3) 3 (3.3) 1.00
Contrast dye 27 (23.5) 8 (33.3) 19 (20.9) .20
Loop diuretics 23 (20) 6 (25) 17 (18.7) .57
NSAIDs 11 (9.6) 2 (8.3) 9 (9.9) 1.00
Vancomycin 63 (54.8) 19 (79.2) 44 (48.4) .04
Concomitant fluids 94 (81.7) 21 (87.5) 73 (80.2) .56
Baseline serum creatinine, mg/dL 0.73 [0.6–1.1] 0.6 [0.5–0.8] 0.8 [0.6–1.1] .07
Highest serum creatinine, mg/dL 0.98 [0.7–1.3] 1.9 [1.1–3] 0.9 [0.7–1.2] <.001
Day of highest serum creatinine, mg/dL 4 [2–5] 4.5 [3–7] 3 [1–5] .003
Admission weight, kg 79.5 [67–98] 89.9 [67–120] 79.1 [67–95] .18
Data are presented as No. (%) or median [interquartile range].
Abbreviations: ACE, angiotensin-converting enzyme; NSAID, nonsteroidal anti-inflammatory drug. 




Unadjusted OR  
(95% CI)
Adjusted OR  
(95% CI)
Obesity 55 (47.8) 2.667 (1.037–6.859) 3.212 (1.191–8.666)
Vancomycin 63 (54.8) 4.059 (1.396–11.804) 4.735 (1.573–14.253)
Abbreviations: CI, confidence interval; OR, odds ratio.
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toxicity in our study, we did not observe a difference in the 
rates of acyclovir-associated nephrotoxicity regardless of weight 
utilized for dosing calculations.
Our study suggests that, in institutions that frequently uti-
lize IV acyclovir, antimicrobial stewardship should target obese 
patients on concomitant vancomycin. Only 15% of our patients 
yielded positive microbiological results, suggesting that acy-
clovir exposure could have been minimized in this popula-
tion and that stewardship efforts should be focused on these 
patients. With HSV PCR results available within 24 hours at 
many institutions, boasting a sensitivity of up to 90%, acyclovir 
therapy should be discontinued as long as clinical judgment 
does not warrant continuation [14]. On January 1, 2017, the 
Joint Commission released standards recommending antibiotic 
timeout at 48 hours as part of a targeted antimicrobial stew-
ardship effort [15]. With nephrotoxicity not occurring until an 
average of 4.5 days after acyclovir initiation, it would be pru-
dent to also assess antiviral agents at that time, particularly in 
patients receiving concomitant vancomycin.
Although our findings provide more insight into the risk 
factors for acyclovir-associated nephrotoxicity, there are several 
limitations. We were unable to find a causative dosing strategy 
to help aid clinicians in selection of an optimal dose for clin-
ical use. Additionally, we had a small sample in our microbio-
logically evaluable population, so we cannot suggest improved 
or worsened efficacy based upon dosing strategy. Furthermore, 
there were more patients who received vancomycin in the 
nephrotoxicity group than in the control group, which makes 
it difficult to discern if the vancomycin or the acyclovir or both 
were responsible for causing nephrotoxicity. Lastly, although we 
attempted to be thorough with our data collection, there may be 
another factor associated with acyclovir-associated toxicity that 
we did not examine.
Acyclovir-associated nephrotoxicity occurred in 21% of 
acyclovir-treated patients and was associated with an increased 
infection-related length of hospital stay after toxicity develop-
ment. Both obesity and concomitant vancomycin usage were 
independent factors that increased risk for the development of 
acyclovir-associated nephrotoxicity. Antimicrobial stewardship 
efforts should target obese patients on acyclovir plus vancomycin 
and discontinue therapy in patients not warranting antiviral cov-
erage to minimize toxicity. Further investigations on nephrotox-
icity in patients on both vancomycin and acyclovir are warranted.
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